BI And Lilly Eye Acute Heart Failure Opportunity For Jardiance

First SGLT Inhibitor To Work In These Patients

Having strongly made the case for Jardiance as a treatment for chronic heart failure, Boehringer Ingelheim and Eli Lilly believe the SGLT2 inhibitor could have a lot of potential in acute heart failure as well after promising data from the EMPULSE study.

heart failure illustration
• Source: Archive

Days after US regulators granted a swift review for Jardiance for another chronic heart failure indication, Boehringer Ingelheim GmbH and Eli Lilly and Company have presented data showing that their blockbuster SGLT2 inhibitor could benefit adults hospitalized with acute heart failure.

The partners have presented data from the 530-patient Phase III EMPULSE trial at the American Heart Association meeting which revealed...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category